Gera Narendra, Baddipadige Raju, Himanshu Verma, Manoj Kumar, Subheet Kumar Jain, Gurleen Kaur Tung, Shubham Thakur, Rasdeep Kaur, Satwinderjeet Kaur, Bharti Sapra, Pankaj Kumar Singh, Om Silakari
Cyclophosphamide (CP) is one of the most widely used anticancer drugs for various malignancies. However, its long-term use leads to ALDH1A1-mediated inactivation and subsequent resistance which necessitates the development of potential ALDH1A1 inhibitors. Currently, ALDH1A1 inhibitors from different chemical classes have been reported, but these failed to reach the market due to safety and efficacy problems. Developing a new treatment from the ground requires a huge amount of time, effort, and money, therefore it is worthwhile to improve CP efficacy by proposing better adjuvants as ALDH1A1 inhibitors...
May 7, 2023: International Journal of Biological Macromolecules